After initially promoting the use of leucovorin (folic acid) as a treatment for certain forms of autism, the US Food and Drug Administration (FDA) has reversed its position five months later. The Trump administration had indicated that this treatment could provide hope for many parents of children with autism, but the FDA has clarified that it remains unapproved for this purpose. The agency stated that leucovorin is still authorized for preventing certain chemotherapy side effects, while it may also be used to treat a rare genetic syndrome known as folate deficiency encephalopathy.

This retraction comes at a time when parents and advocates for children with autism are seeking effective treatments. The initial announcement created significant anticipation, as many viewed it as a breakthrough, despite the lack of scientific evidence supporting the use of leucovorin for autism. Now, the FDA’s decision may lead to disappointment among those who were hopeful for new options in managing autism spectrum disorders, which are complex and varied in their manifestations.

The implications of this decision are significant, especially in the context of ongoing debates about treatments for autism. The FDA's reversal underscores the importance of regulatory oversight in protecting patients from unproven treatments, and it highlights the need for continued research into effective therapies for autism. Such developments are crucial for the well-being of those affected by autism and for providing parents with reliable information regarding treatment options.